Clinical Trial to Evaluate Efficacy and Safety of of Autologous Mesenchymal Stem Cells (MSC) Injected Intracavernously

This looks like a challenging but not hopeless Phase 2 readout. The primary endpoint is clinically relevant—a 6-month change in IIEF erectile-function score—but it is patient-reported and therefore vulnerable to placebo, expectation, and site-level variability, which is especially important in erectile dysfunction. The intervention is an autologous MSC product given intracavernously, a biologically plausible regenerative approach, but one that also brings manufacturing, consistency, and dose-execution risk compared with a conventional drug. As a Phase 2 study, it is more likely to be exploratory and sample-size limited, increasing noise and reducing the chance of a cleanly persuasive efficacy signal. The endpoint wording emphasizes change from baseline with ANCOVA across administration groups, but it does not clearly present a hard superiority framework, which raises ambiguity around what will count as definitively positive. Trial completion lowers operational risk, yet the post-completion disclosure window adds some readout uncertainty. Overall, I put the odds of an unambiguously positive result below even.

This Phase 2 single-blind randomized trial (N=54) evaluates autologous BM-MSC intracavernosal injection for post-prostatectomy ED, measuring IIEF EF domain change at 6 months via ANCOVA. Prior open-label Phase 1 studies of intracavernosal MSC show IIEF improvements of 5-11 points at 6 months, but effects are transient and evidence remains inconclusive per a 2025 meta-analysis. Critically, this is the first properly randomized controlled Phase 2 for this product — the bar is substantially higher than prior single-arm studies that lacked placebo controls. The trial experienced multiple timeline delays (primary completion pushed from Aug 2022 to Jan 2026), suggesting operational difficulties. Despite being 85 days past primary completion, no results have been disclosed, which is a mildly negative signal though not uncommon for Korean sponsors. The small sample split across multiple dosing arms likely limits statistical power for the ANCOVA primary analysis. Pharmicell's track record includes a terminated trial (Cellgram-DC) due to recruitment failure. The biological plausibility is moderate but stem cell therapies for ED remain experimental with high failure rates in controlled settings.

This Phase 2 trial evaluates autologous MSC therapy for erectile dysfunction using a validated endpoint (IIEF score change at 6 months). Phase 2 trials historically succeed approximately 50% of the time, and MSC therapies have shown mixed results across indications. The trial is now completed, suggesting results are available, but the sponsor has not disclosed outcomes publicly. The intracavernous injection route is invasive but MSC therapy generally carries a acceptable safety profile. The primary endpoint uses the well-established IIEF questionnaire, which strengthens the validity of any positive signal. However, the novelty of MSC therapy for ED and typical Phase 2 uncertainty support a probability below even odds. Given these factors, the intrinsic probability of a positive outcome appears modestly below 50%.

The trial is a Phase 2 study in erectile dysfunction using autologous mesenchymal stem cells (Cellgram-ED). The primary endpoint is change in IIEF score at 6 months, a patient-reported outcome subject to placebo effects. While the trial is completed, no results are disclosed, creating high disclosure risk. Prior data for stem cell therapies in ED is mixed and often from small, open-label studies. The sponsor, Pharmicell, is a small-cap biotech. The operational risk is moderate given the completed status, but the intrinsic probability of a definitively positive result that meets rigorous statistical significance and magnitude thresholds is below 50%.

Phase 2 trial of autologous MSCs (Cellgram-ED) injected intracavernously for erectile dysfunction leverages regenerative potential via paracrine signaling, angiogenesis, and anti-fibrosis, mechanistically sound for vasculogenic/neuropathic ED. Patient population: ED patients suitable for invasive therapy, likely refractory to PDE5i. Primary endpoint—6-month IIEF-EF score change vs baseline (scale 6-30)—is gold-standard, validated, responsive PRO; ANCOVA across administration groups provides robust dose-response analysis, powering detection of clinically meaningful ~4-6 point shifts. Design likely multi-arm (doses), baseline control adequate for Phase 2 though placebo ideal; uncontrolled common in cell therapy, favors positive if effect real. No prior data in fields, but autologous sourcing ensures safety (minimal rejection), prior small ED-MSC studies show EF gains. Operational: completed on/pre-schedule (-85 days past primary), data locked. Disclosure risk low-moderate: public sponsor (Pharmicell), Phase 2 readout standard, minor delay typical post-completion. Strong endpoint quality, execution, MoA support 62% prob of positive results (stat sig primary met).

This Phase 2 trial for Cellgram-ED in erectile dysfunction has completed, with a primary completion date in January 2026. The study uses the IIEF-EF domain, a validated and sensitive instrument, as its primary endpoint, which is appropriate for detecting clinically meaningful change. The intracavernous injection of autologous MSCs is a plausible mechanism for tissue regeneration, supported by positive signals in prior small-scale studies for similar indications. The sponsor, Pharmicell, has experience with MSC products. However, Phase 2 trials in regenerative medicine often face efficacy challenges, and the placebo response in ED trials is typically high, which introduces variance. While the trial design is sound, the inherent uncertainty of novel cell therapies and the lack of publicly disclosed topline results prevent a higher confidence rating. The probability leans positive based on the biological rationale and design, but execution risk remains.

This completed Phase 2 trial of Cellgram-ED for erectile dysfunction has favorable structural features. The primary endpoint uses IIEF-EF score, a validated regulatory standard for ED trials with established clinical meaningfulness thresholds (4-point improvement). The 6-month follow-up duration is appropriate for stem cell mechanism assessment. Autologous MSC intracavernous injection has plausible mechanistic rationale for vascular/structural ED pathology. Sponsor Pharmicell is an established Korean stem cell company with prior regulatory approvals. The trial completed on schedule without disclosed safety holds, suggesting clean data collection. Phase 2 studies in ED with cell therapies have historically shown signal in similar mechanisms. The primary completion date was January 2026, so results should be imminent. Disclosure risk is moderate given Korean reporting requirements. Overall, positive readout probability exceeds 60% based on endpoint validity, clean execution, and mechanistic precedent.

The Phase 2 trial of Cellgram-ED for post-radical prostatectomy erectile dysfunction (ED) faces a difficult clinical hurdle. While early open-label data showed promise, post-prostatectomy ED is notoriously hard to treat due to significant cavernous nerve injury and structural damage. This trial randomized 54 patients to receive either a single intracavernous injection of autologous MSCs or placebo, alongside daily/on-demand PDE5 inhibitors. With approximately 27 patients per arm, the trial is only statistically powered to detect a relatively large effect size. Stem cell therapies often struggle in placebo-controlled settings due to historically high placebo responses on subjective, patient-reported endpoints like the IIEF. Although the trial's single-blind design could theoretically allow for some investigator bias to seep into the assessments, the very small sample size and the underlying biological severity of post-prostatectomy ED make achieving a statistically significant delta on the 6-month IIEF-EF score change quite challenging. Given these factors, the intrinsic probability of a definitively positive result is estimated to be slightly below a coin flip.

The trial is a Phase 2 clinical trial evaluating the efficacy and safety of autologous Mesenchymal Stem Cells (MSC) injected intracavernously for Erectile Dysfunction. The primary endpoint is the change in EF score in the International Erectile Function Questionnaire (IIEF) at administration of the clinical trial drug compared to the baseline value. Given that the trial is completed and the intervention is a biological product with a clear mechanism of action, there is a reasonable chance of positive results. However, the sample size and trial design may impact the reliability of the results.